
OptimizeRx Corp (OPRX) Stock Forecast & Price Target
OptimizeRx Corp (OPRX) Analyst Ratings
Bulls say
OptimizeRx Corp is positioned for substantial growth as the shift from in-person to digital pharmaceutical interactions continues, with projected revenue growth in the high teens to low twenties while expanding margins. The company's current operational capabilities support a revenue run-rate of approximately $150 million, which indicates potential operating leverage over the next few years. Additionally, OptimizeRx has reported a significant increase in gross margin and EBITDA, showcasing its effective cost management and enhanced revenue generation from its expanded product offerings in the healthcare market.
Bears say
OptimizeRx Corp has issued a downward revision of its 2026 revenue guidance, adjusting it to a range of $109 million to $114 million, which indicates only modest growth compared to previous expectations and highlights significant near-term challenges. Revenue growth is expected to decline by approximately 10% in the first half of 2026, primarily due to large pharmaceutical clients facing pressure from the Trump Administration's "most favored nation" pricing initiative. Additionally, the company's net revenue retention (NRR) has dropped significantly, reflecting reduced spending from pharma clients, which, combined with decreased visibility and lower contracted revenue, suggests a concerning outlook for future performance.
This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.
OptimizeRx Corp (OPRX) Analyst Forecast & Price Prediction
Start investing in OptimizeRx Corp (OPRX)
Order type
Buy in
Order amount
Est. shares
0 shares